comparemela.com

Page 10 - Webinar Catalent News Today : Breaking News, Live Updates & Top Stories | Vimarsana

07 01 21 -- The U S Drug Pricing System Needs To Be Fixed

07 01 21 -- The U S Drug Pricing System Needs To Be Fixed
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.

05 10 21 -- The Benefits Of A Functional Service Provider (FSP) Model In Uncertain Times

05.10.21 The Benefits Of A Functional Service Provider (FSP) Model In Uncertain Times     YPrime eCOA Platform Isn’t it about time for a globally proven eCOA technology that gives you peace of mind? One that provides a better user experience for patients, sites, and sponsors? YPrime’s eCOA platform delivers even the most complex protocol seamlessly. Developed to integrate intelligently with your other technologies, all modalities are available for site- or home-based trials and paired with secure web backup for guaranteed accuracy and confident, informed decision-making. Featured Editorial Clinical Leader Contract research outsourcing (CRO) can be a challenging endeavor even in the best of times. Simply selecting the right model can be a difficult chore, and then there are the tasks of selecting the right partners, preparing contracts, and conducting oversight. When operating in uncertain times, the process becomes significantly more

04 07 21 -- AI Speeds Patient Recruitment At Health Quest

04.07.21 AI Speeds Patient Recruitment At Health Quest   On this episode of Business of Biotech, Nevan Charles Elam, J.D., founder of Rezolute Bio, shares the company s rationale for pursuing congenital hyperinsulinism and diabetic macular edema therapeutics by leveraging monoclonal antibodies (mAbs) and discusses the company s approach to process development and manufacturing. Listen now and subscribe so you never miss an episode. Featured Editorial By Ed Miseta, chief editor, Clinical Leader Artificial intelligence (AI) has the potential to disrupt and revolutionize many aspects of clinical trials. One area in which it is already making an impact is patient recruitment. Mining electronic medical records (EMRs) for patients meeting inclusion and exclusion criteria can be tedious and time-consuming work but is a chore that seems ideal for an AI solution.

04 06 21 -- A Risk Assessment Checklist Of Nitrosamine Impurities In Oral Solid Dose Drugs

04.06.21 A Risk Assessment Checklist Of Nitrosamine Impurities In Oral Solid Dose Drugs       Treatment for advanced cases of lung cancer is challenging. Delivery by inhalation is an ideal way to circumvent many of the drawbacks associated with lung cancer treatment.   Attend this webinar to understand the pros and cons of existing therapies and learn why spray drying is a useful particle engineering technique for the manufacture of pulmonary lung cancer treatments.   By Amol Galande, Ajay Pazhayattil, and Sanjay Sharma Nitrosamine impurities such as N-nitrosodimethylamine (NDMA) are being identified in high-volume drug products such as valsartan, losartan, irbesartan, and ranitidine at levels well above the acceptable daily intake limits. 

03 01 21 -- 10 Years Of Progress In 10 Months: 2020 Was A Reset Year For Pharma

03.01.21 10 Years Of Progress In 10 Months: 2020 Was A Reset Year For Pharma   Sponsor From the front lines, hear real-life success stories in the strategy and execution of randomized trial supply management (RTSM). This webinar will showcase how joining forces with the right partner allowed these pharma professionals to learn and deliver best practices on design considerations, reducing user acceptance testing (UAT) scope and timelines for RTSM builds among the rigors and day-to-day challenges of study conduct. Register for free today. Featured Editorial By Ed Miseta, chief editor, Clinical Leader A new report from McKinsey & Company highlights why 2020, despite the COVID-19 pandemic, was a banner year for innovation in drug development, and why we should be optimistic for the future of the industry. 

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.